(S)-(+)-Rolipram ((+)-Rolipram)是一种cAMP依赖性磷酸二酯酶4 (PDE4)抑制剂,并能抑制人单核细胞中肿瘤坏死因子α(TNFα)的产生。
|
英文别名 (English Synonym) |
S- (+)-Rolipram |
|
中文名称 (Chinese Name) |
(S)-(+)-咯利普兰；(+)-咯利普兰 |
|
靶点 (Target) |
PDE |
|
通路 (Pathway) |
Protease/Metabolic Enzyme |
|
CAS号 (CAS NO.) |
85416-73-5 |
|
分子式 (Formula) |
C16H21NO3 |
|
分子量 (Molecular Weight) |
275.34 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Semmler J, Wachtel H, Endres S. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells. Int J Immunopharmacol. 1993 Apr,15(3):409-13. doi: 10.1016/0192-0561(93)90052-z. PMID: 8505151.[2]Wachtel H. Neurotropic effects of the optical isomers of the selective adenosine cyclic 3',5'-monophosphate phosphodiesterase inhibitor rolipram in rats in-vivo. J Pharm Pharmacol. 1983 Jul,35(7):440-4. doi: 10.1111/j.2042-7158.1983.tb04318.x. PMID: 6136585.
